 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Conformational restrictions in the active site of unliganded caspase-3
|
|
Structure:
|
 |
Apopain. Chain: a. Synonym: cysteine protease cpp32, yama protein, cpp-32, cas casp-3, srebp cleavage activity 1, sca-1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: casp3 or cpp32. Expressed in: escherichia coli bl21. Expression_system_taxid: 511693.
|
|
Biol. unit:
|
 |
Dimer (from PDB file)
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.249
|
R-free:
|
0.278
|
|
|
Authors:
|
 |
C.-Z.Ni,C.Li,J.C.Wu,A.P.Spada,K.R.Ely
|
|
Key ref:
|
 |
C.Z.Ni
et al.
(2003).
Conformational restrictions in the active site of unliganded human caspase-3.
J Mol Recognit,
16,
121-124.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
04-Sep-03
|
Release date:
|
07-Oct-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P42574
(CASP3_HUMAN) -
Caspase-3
|
|
|
|
Seq: Struc:
|
 |
 |
 |
277 a.a.
232 a.a.*
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
plasma membrane
|
7 terms
|
 |
|
Biological process
|
response to DNA damage stimulus
|
33 terms
|
 |
|
Biochemical function
|
protein binding
|
7 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Recognit
16:121-124
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Conformational restrictions in the active site of unliganded human caspase-3.
|
|
C.Z.Ni,
C.Li,
J.C.Wu,
A.P.Spada,
K.R.Ely.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Caspases are cysteine proteases that play a critical role in the initiation and
regulation of apoptosis. These enzymes act in a cascade to promote cell death
through proteolytic cleavage of intracellular proteins. Since activation of
apoptosis is implicated in human diseases such as cancer and neurodegenerative
disorders, caspases are targets for drugs designed to modulate their action.
Active caspases are heterodimeric enzymes with two symmetrically arranged active
sites at opposite ends of the molecule. A number of crystal structures of
caspases with peptides or proteins bound at the active sites have defined the
mechanism of action of these enzymes, but molecular information about the active
sites before substrate engagement has been lacking. As part of a study of
peptidyl inhibitors of caspase-3, we crystallized a complex where the inhibitor
did not bind in the active site. Here we present the crystal structure of the
unoccupied substrate-binding site of caspase-3. No large conformational
differences were apparent when this site was compared with that in
enzyme-inhibitor complexes. Instead, the 1.9 A structure reveals critical side
chain movements in a hydrophobic pocket in the active site. Notably, the side
chain of tyrosine204 is rotated by approximately 90 degrees so that the phenol
group occupies the S2 subsite in the active site. Thus, binding of substrate or
inhibitors is impeded unless rotation of this side chain opens the area. The
positions of these side chains may have important implications for the directed
design of inhibitors of caspase-3 or caspase-7.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
N.Keller,
M.G.Grütter,
and
O.Zerbe
(2010).
Studies of the molecular mechanism of caspase-8 activation by solution NMR.
|
| |
Cell Death Differ, 17,
710-718.
|
 |
|
|
|
|
 |
S.Okazaki,
F.Ogawa,
Y.Iwata,
T.Hara,
E.Muroi,
K.Komura,
M.Takenaka,
K.Shimizu,
M.Hasegawa,
M.Fujimoto,
and
S.Sato
(2010).
Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis.
|
| |
Rheumatol Int, 30,
871-878.
|
 |
|
|
|
|
 |
J.Agniswamy,
B.Fang,
and
I.T.Weber
(2009).
Conformational similarity in the activation of caspase-3 and -7 revealed by the unliganded and inhibited structures of caspase-7.
|
| |
Apoptosis, 14,
1135-1144.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Wang,
R.H.Mach,
and
D.E.Reichert
(2009).
Docking and 3D-QSAR studies on isatin sulfonamide analogues as caspase-3 inhibitors.
|
| |
J Chem Inf Model, 49,
1963-1973.
|
 |
|
|
|
|
 |
W.A.Witkowski,
and
J.A.Hardy
(2009).
L2' loop is critical for caspase-7 active site formation.
|
| |
Protein Sci, 18,
1459-1468.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Agniswamy,
B.Fang,
and
I.T.Weber
(2007).
Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis.
|
| |
FEBS J, 274,
4752-4765.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.J.Romanowski,
J.M.Scheer,
T.O'Brien,
and
R.S.McDowell
(2004).
Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding.
|
| |
Structure, 12,
1361-1371.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.J.Riedl,
and
Y.Shi
(2004).
Molecular mechanisms of caspase regulation during apoptosis.
|
| |
Nat Rev Mol Cell Biol, 5,
897-907.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|